National Institute on Alcohol Abuse and Alcoholism (NIAAA)
about
Age-17 Follow-up of Home Visiting InterventionDo Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement TherapyVarenicline to Reduce Alcohol Consumption in Heavy DrinkersBiomarker Study of Acamprosate in SchizophreniaUltra-brief Intervention for Problem DrinkersSeroquel for Frequent, Heavy DrinkersAn Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol DependenceCM Treatment for Alcohol Dependence Using New TechnologyAlcohol Myopia, Objectification, and Sexual AssaultDWI Offenders and Their Families App for SmartphonesMechanisms for Alcohol Treatment Change [MATCH] StudyAlcohol Disorder hOsPital Treatment TrialHarm Reduction With Pharmacotherapy (HaRP)Development of an Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in UgandaChicago Social Drinking ProjectEvaluating Within-Person and Between-Person Effects Of A Personalized Normative Feedback Intervention On Drinking As They Are Moderated By Self-DeterminationA Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy DrinkersPharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUDDUR-928 in Patients With Alcoholic HepatitisVitamin C Infusion for TReatment in Sepsis and Alcoholic HepatitisAllogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.Integrating Combined Therapies for Persons With Co-occurring DisordersIntegrated Approaches for Identifying Molecular Targets in Alcoholic HepatitisWeb Intervention for Concerned Partners to Prevent Service Member Alcohol Abuse AbuseZinc Supplementation in Alcoholic CirrhosisCognitive Retraining and Brain Stimulation for Alcohol UseNaltrexone for Individuals of East Asian DescentDevelopment of Ibudilast for Alcohol Use DisorderEfficacy and Safety of High Dose Baclofen for Alcohol DependencePreventing FAS/ARND in Russian ChildrenAssessing the Fit of Motivational Interviewing by Cultures With AdolescentsTrial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)Intervention to Enhance PrEP Uptake and Adherence in a Community-Based SettingExtended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department UsersTexas Family Health Patterns: A Study Across GenerationsEvaluating Interventions for Alcohol Use DisorderImproving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic SettingsEffect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory FailureHIV Risk and Prevention in WomenOxytocin Treatment of Alcohol Dependence
P767
Unit and Clinic Evaluation, Screening, Assessment, and ManagementGenetics of the Acute Response to Alcohol in Social DrinkersExploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot StudyFluoxetine and Bupropion to Treat Patients With Depression and AlcoholismMedication and Counseling for Controlled Drinking (Project SMART)Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)Naltrexone, Craving, and DrinkingAlcoholism Assessment and TreatmentA Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use DisorderDopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRIBehavior and Naltrexone Treatment for AlcoholicsBrain Dopaminergic Signaling in Opioid Use DisordersA Novel Compound for Alcoholism TreatmentDietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body CompositionThe Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and NonalcoholicsGhrelin Signaling Via GOAT Inhibition in Alcohol Use DisorderBrain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy PeopleStudy of Structural ImagingBrain Inflammation and Function in AlcoholismMeasuring Effects of Alcohol on Brain ChemistryA Novel Compound for Alcoholism Treatment: A Translational StrategyIntranasal Oxytocin for the Treatment of Alcohol Use DisorderNicotinic Receptor Genetic Variation and Alcohol RewardNational Epidemiologic Survey on Alcohol and Related Conditions-IIICorticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^ABT-436 for Alcohol DependenceThe Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol InfusionBaclofen for Treating Anxiety and AlcoholismCharacterization Imaging Instruments in Alcoholics and Non-AlcoholicsComputer-Assisted Self-Administration of EthanolEpi-Genetic Modulators of Fear Extinction in Alcohol DependenceHuman Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and WakefulnessDopamine Rhythms in Health and AddictionReliability of the Human Brain ConnectomeTraits Associated With Early Life Stress Among Treatment-Seeking AlcoholicsBehavioral and Functional MRI Task Development, Implementation, and TestingLevetiracetam XR in Very Heavy DrinkersThe Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSDCRF1 Antagonist GSK561679 in AlcoholismAripiprazole and Topiramate on Free-Choice Alcohol Use
P859
Q64041288-D3D44187-F591-4152-A5FB-8F40236B17F6Q64043088-E99A7B82-4002-4FE5-817E-3688A89A9A3FQ64043898-B46FADA7-2388-485B-AEF4-95F07110FAA4Q64045261-1C8037F3-0941-4578-BDCC-1B331F0B4B1CQ64045277-66106EBC-6B1B-4184-B232-A799D7E72605Q64046990-EA453F1C-5274-417E-89D2-03CD0D2FE45FQ64048328-351D62DF-6D2E-44A9-9DF3-6D6BE6F09271Q64123425-B02F67DF-279C-4F80-9C25-2521B9A54CA9Q64123808-485E7F40-C375-459F-9340-FDC2B47E4F44Q64139928-887999B2-2355-49BD-926F-0056FBF8D3D3Q64151172-53E6BFD6-D582-464A-B8A3-EAD1D349070BQ64151650-5FCC2739-CD99-4A6E-826E-68B2A865DFDBQ64151911-B046AA7F-D074-4A1D-8644-51F394EC16C3Q64172453-1C07F9F9-928F-45BF-AF3B-01DE112D53B4Q64172845-E40BB74C-CF01-4BB8-8E4B-EB8569A7DD87Q64184111-B7815BE5-1D3F-44E2-A4AE-4156F7919BC4Q64187299-A7F310C9-593B-418C-B1E5-94AB638ED7C6Q64188172-8531302A-A70B-4665-8BB2-D75D98026FCCQ64189248-54463F30-F8A4-4229-808E-6AB2F6298F2AQ64189422-F32E83ED-3398-45B4-9A92-5F56CB8ACAC1Q64189624-623BB185-EF6B-4A8A-9F5E-0F14FE91F052Q64216557-132E062A-2CF9-421B-9CF7-EBC0A5E0DA3AQ64222191-D7CE955D-397B-4D26-AEAB-740052B4F090Q64222451-D4AD0D47-C9EE-4CE4-98C9-B70E69046A19Q64222532-831F2564-D289-4D90-93D5-6F3A40524C95Q64348606-3AE26D08-5BC4-4A49-9D16-4D60C0856639Q64349365-C2A6DB09-173D-4C35-A84A-E3743B8078F2Q64349682-1412799D-EE79-47F9-8CAA-CDC99D81CA25Q64352502-C137377B-1639-4967-9DF5-543CCFAFA01BQ64353172-4C823F35-66C6-4A33-BA64-1B39746F0677Q64354231-F14CA6CA-AED1-4282-BCE4-81F50400A0DDQ64375889-0A6DAF62-310A-4686-877B-6F81E875E4D3Q64392630-117EB669-3F6D-4F7A-879A-2425FE5B5D4DQ64396120-3203E681-66F1-4BF7-810C-CB6DEE995A85Q64397151-059E25A8-D903-4EF9-9002-8C43DBDD374EQ64397190-7FF7B12A-6442-4C68-83D5-3A9EDD6AC11FQ64397301-21401F03-8DFA-4F47-A4AC-3F96347736A4Q64599277-8A3372D0-B573-472C-9253-EC329393606AQ64601016-1300DCA1-1C5B-4A42-8799-11539D55332CQ64602182-C413096D-381F-47E8-BA7F-087ADE603027
P767
Q61864718-C4EDD7B7-EDBE-41EF-BF60-904C4F6AEBC4Q61864905-750F8B7A-E119-447F-BE30-8D2BEBBAC9E1Q61909883-9C42A02F-4D20-4C1A-967A-014403625172Q61923095-0B80E80A-36BF-4ACC-BEA8-2D1CF49C3189Q61924750-DDD586D9-E03D-482C-877D-10689954E564Q62040729-92FC4529-015B-415C-ACFD-D778E8A66320Q62041164-010E1C5D-7913-4630-B694-D576091E6838Q62105732-4BA03281-158D-47BA-9237-D3401DD642EEQ62814641-D40DCED4-03E4-4DB7-B8AE-5890384F103EQ63534299-3CFE76AB-4568-4490-B3C9-C2BCF4F54838Q63571319-8835E8DC-3378-4AAE-BA11-D5A20FACF2ACQ63573204-BFC85132-5F72-47FC-8CCB-E5B6F6643B90Q63574927-CB0F95EE-3ED5-4D5B-84C3-F2DCDC42F162Q63576405-DAC9535A-C345-4B96-AA7C-750E1BA976FFQ63577421-12924AD2-46B6-4B51-AADC-421B42541BB2Q63577602-43E4A1DF-613F-4DA1-A710-F89F3EC896C0Q63578297-72D580EC-05C5-4A48-9247-F3FF01780DECQ63578731-57C8FEE9-2785-494C-A4BF-F31443612D3FQ63590621-326EB259-3A0D-4B5C-A351-82E44C8AAA0DQ63591069-36EEE1D8-4FED-44B0-8421-B7E4BFE0F327Q63807867-B8B4F1E5-7F67-4E53-8F2D-CFF6C6CD7389Q63808364-185FA288-3E99-4512-ABF6-2A020CC5778BQ63811946-F7ECFB6B-D324-4D52-B012-051ED0478FEAQ63815526-CFCAA2E9-C3B3-4562-9E99-EBA5247BB4A8Q63816653-1AF79ADF-27CB-4DC2-9941-78696645D362Q63843572-2288B797-78F2-4914-ADFA-785B009A913FQ64048351-BFAA6850-BD3D-4811-B41F-53C2E3CCEB70Q64071189-0F1C1B9B-755F-40DE-B0EC-191ACA789649Q64140222-9E75C3D7-AD1F-4A2F-908F-D2F4154BD4BEQ64187621-8F4D3926-25F6-4923-971A-5236B865002CQ64397049-2EA0BC52-C77A-4FEA-8454-A9B6EA3FE4A1Q64597762-0343C91A-74AD-454E-A5B2-BC9CA92D9CA5Q64607151-40256D69-1918-41EB-95B7-DD514628784FQ64607260-93401FFB-7B73-47AB-94AA-A74647CC4411Q64608830-AE7F2B5A-DE7C-48DC-9477-23A403CE08B2Q64611809-15E83600-B98C-4E20-83F4-72EDD70DCB2DQ64663945-B762C035-407D-455E-9FF3-E95EDC3855D4Q64677294-BCD09C2D-5C43-482E-82F2-1FFCCE81EAF5Q64678532-8D128458-6B22-4051-845E-DC5CF4F3A5EBQ64679160-BDFE6BE1-7733-40C4-92D8-D97400628415
P859
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
description
article
@en
artikull shkencor
@sq
artículu científicu
@ast
wetenschappelijk artikel
@nl
գիտական հոդված
@hy
գիտական յօդուած
@hyw
ലേഖനം
@ml
name
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@ast
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@en
type
label
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@ast
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@en
prefLabel
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@ast
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@en
P3181
P1476
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
@en
P2093
Kelly Boyer
P3181
P356
10.4135/9781412963855.N839